October 7, 2025 — Leads & Copy — Kairos Pharma, Ltd. (NYSE American: KAPA) will present at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany from October 17–21, 2025. The presentation will highlight interim analysis results from a Phase 2 trial evaluating ENV105 (carotuximab), a first-in-class CD105 antagonist, in combination with apalutamide for metastatic castration-resistant prostate cancer (mCRPC).
The trial is enrolling 100 men with mCRPC who have progressed on prior hormone therapies at Cedars-Sinai Medical Center, City of Hope, and Huntsman Cancer Institute at the University of Utah. Patients are randomized to receive apalutamide with or without ENV105.
According to Neil Bhowmick, PhD, Kairos Pharma CSO, the data demonstrates encouraging safety and early efficacy findings from the Phase 2 trial, and the ESMO Congress is an important venue to share the therapeutic potential of ENV105 for patients with limited treatment options after hormone therapy resistance develops.
Prostate cancer remains one of the most diagnosed cancers in men, with over a million new cases annually in the U.S. Resistance to androgen-targeted therapies represents a major clinical challenge in patients with mCRPC.
For more information about the study, visit: https://clinicaltrials.gov/study/NCT05534646
Contact: Neil Bhowmick, PhD, Kairos Pharma CSO.
Source: Kairos Pharma
